<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02408146</url>
  </required_header>
  <id_info>
    <org_study_id>Lianxin-001</org_study_id>
    <nct_id>NCT02408146</nct_id>
  </id_info>
  <brief_title>The Effect of Parecoxib Sodium Intravenous Patient-controlled Analgesia in Laparotomic Liver Resection</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>First Affiliated Hospital of Harbin Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>First Affiliated Hospital of Harbin Medical University</source>
  <brief_summary>
    <textblock>
      The investigators hypothesized that using new intravenous infusion pump of patient-controlled
      analgesia (parecoxib sodium 1 mg/mL + normal saline) would significantly improve
      postoperative pain control compare to conventional intravenous infusion pump of
      patient-controlled analgesia (fentanyl citrate 20 mg/mL/kg + ondansetron hydrochloride 16
      mg/8 mL + normal saline). This prospective randomized controlled trial was designed to
      evaluate the benefit of new intravenous infusion pump of patient-controlled analgesia
      (parecoxib sodium 1 mg/mL + normal saline) for postoperative analgesia after laparotomic
      liver resection.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2014</start_date>
  <primary_completion_date type="Anticipated">July 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The measure is a composite outcome measure consisting of multiple measures,pain scores, sedation, nausea, pruritus, and respiratory rate.</measure>
    <time_frame>With or without changes in the three days after surgery</time_frame>
    <description>Pain scores are evaluated with a visual analog scale of 0 to 100 and are measured at rest and with movement such as cough or incentive spirometry at 6, 9, 12, 18, 24, 36, 48 and 72 hours. Sedation, nausea, and pruritus are also measured at 6, 9, 12, 18, 24, 36, 48 and 72 hours. All the measures count together to get a composite outcome.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Pain, Postoperative</condition>
  <arm_group>
    <arm_group_label>conventional intravenous infusion pump</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The first group receives conventional intravenous infusion pump of patient-controlled analgesia.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>parecoxib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The second group has oral celecoxib before surgery, then receives parecoxib sodium intravenously guttae after surgery.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>new intravenous infusion pump</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The third group uses new intravenous infusion pump of patient-controlled analgesia after surgery.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>conventional intravenous infusion pump</intervention_name>
    <description>The first group receives conventional intravenous infusion pump of patient-controlled analgesia (fentanyl citrate 20 mg/mL/kg + ondansetron hydrochloride 16 mg/8 mL + normal saline) for three days after surgery. The pump is infused continuously at the basic flow rate of 2 mL/h, 0.5 mL of bolus can be injected if the patients press the button once upon experiencing pain. The lock-out time for each bolus injection is 15 minutes.</description>
    <arm_group_label>conventional intravenous infusion pump</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>parecoxib</intervention_name>
    <description>The second group has oral celecoxib before surgery, then receives 40 mg parecoxib sodium intravenously guttae twice a day for three days after surgery.</description>
    <arm_group_label>parecoxib</arm_group_label>
    <arm_group_label>new intravenous infusion pump</arm_group_label>
    <other_name>CAS number: 202409-33-4</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>intravenous infusion pump of patient-controlled analgesia</intervention_name>
    <description>The third group has oral celecoxib before surgery, and receives 40 mg parecoxib sodium intravenously guttae immediately after surgery, then uses new intravenous infusion pump of patient-controlled analgesia (parecoxib sodium 1 mg/mL + normal saline) for three days after surgery. The pump is infused continuously at the basic flow rate of 2 mL/h, 0.5 mL of bolus can be injected if the patients press the button once upon experiencing pain. The lock-out time for each bolus injection is 15 minutes.</description>
    <arm_group_label>new intravenous infusion pump</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fentanyl citrate+ ondansetron hydrochloride + normal saline</intervention_name>
    <arm_group_label>conventional intravenous infusion pump</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>celecoxib</intervention_name>
    <arm_group_label>parecoxib</arm_group_label>
    <arm_group_label>new intravenous infusion pump</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Patients need laparotomic liver resection.

        Exclusion Criteria:

        Patients with contraindications to spinal anesthesia or intrathecal morphine, difficulty
        understanding passive cutaneous anaphylaxis, a history of drug dependence or chronic pain,
        body mass index greater than 35 kg/m2, or history of sleep apnea were excluded from this
        study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Lianxin Liu, M.D.</last_name>
    <phone>86-451-85553886</phone>
    <phone_ext>3886</phone_ext>
    <email>liulianxin@hotmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jiabei Wang, PhD</last_name>
    <phone>86-451-85555048</phone>
    <phone_ext>5048</phone_ext>
    <email>inn_2001@126.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>harbin Medical University</name>
      <address>
        <city>Harbin</city>
        <state>Heilongjiang</state>
        <zip>150086</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jiabei Wang, PhD</last_name>
      <phone>86-451-85555049</phone>
      <email>inn_2001@126.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 1, 2014</study_first_submitted>
  <study_first_submitted_qc>April 2, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 3, 2015</study_first_posted>
  <last_update_submitted>April 2, 2015</last_update_submitted>
  <last_update_submitted_qc>April 2, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 3, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pain, Postoperative</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fentanyl</mesh_term>
    <mesh_term>Celecoxib</mesh_term>
    <mesh_term>Parecoxib</mesh_term>
    <mesh_term>Ondansetron</mesh_term>
    <mesh_term>Citric Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

